Evidence map›Paper›PMID 35024180›Full record

ReviewJournal of advanced research2021

Activation of Nrf2/HO-1 signaling: An important molecular mechanism of herbal medicine in the treatment of atherosclerosis

Qing Zhang, Jia Liu, Huxinyue Duan, Ruolan Li, Wei Peng, Chunjie Wu

Open access · goldAbstract readReview
In one paragraph

Review in Journal of advanced research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 397 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
397citing papers in PubMed, 1 pooled it
37.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

397 citing papers in PubMed, 1 synthesis or guideline pooled it, 744 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Therapeutic potential ofPharmaceutical biology · 2026
    Review
  5. Article
  6. Antioxidants (Basel, Switzerland) · 2026
    Article
  7. Article
  8. Review
  9. Furong Tongmai Capsule Ameliorates Atherosclerosis in ApoEJournal of cellular and molecular medicine · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Efficacy of Watercress (Antioxidants (Basel, Switzerland) · 2026
    Article
  17. Article
  18. Review
  19. Low-Molecular-Weight Fucoidan fromFoods (Basel, Switzerland) · 2026
    Article
  20. Review

337 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Qing ZhangSchool of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611130, PR China.
Jia LiuSchool of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611130, PR China.
Huxinyue DuanSchool of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611130, PR China.
Ruolan LiSchool of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611130, PR China.
Wei PengSchool of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611130, PR China.
Chunjie WuSchool of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611130, PR China.
Chengdu University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Recently, Nrf2/HO-1 has received extensive attention as the main regulatory pathway of intracellular defense against oxidative stress and is considered an ideal target for alleviating endothelial cell (EC) injury. Objectives: This paper aimed to summarized the natural monomers/extracts that potentially exert protective effects against oxidative stress in ECs. Methods: A literature search was carried out regarding our topic with the keywords of "atherosclerosis" or "Nrf2/HO-1" or "vascular endothelial cells" or "oxidative stress" or "Herbal medicine" or "natural products" or "natural extracts" or "natural compounds" or "traditional Chinese medicines" based on classic books of herbal medicine and scientific databases including Pubmed, SciFinder, Scopus, the Web of Science, GoogleScholar, BaiduScholar, and others. Then, we analyzed the possible molecular mechanisms for different types of natural compounds in the treatment of atherosclerosis via the protection of vascular endothelial cells from oxidative stress. In addition, perspectives for possible future studies are discussed. Results: These agents with protective effects against oxidative stress in ECs mainly include phenylpropanoids, flavonoids, terpenoids, and alkaloids. Most of these agents alleviate cell apoptosis in ECs due to oxidative stress, and the mechanisms are related to Nrf2/HO-1 signaling activation. However, despite continued progress in research on various aspects of natural agents exerting protective effects against EC injury by activating Nrf2/HO-1 signaling, the development of new drugs for the treatment of atherosclerosis (AS) and other CVDs based on these agents will require more detailed preclinical and clinical studies. Conclusion: Our present paper provides updated information of natural agents with protective activities on ECs against oxidative stress by activating Nrf2/HO-1. We hope this review will provide some directions for the further development of novel candidate drugs from natural agents for the treatment of AS and other CVDs.

Indexed as

AtherosclerosisPharmaceutical PreparationsEndothelial CellsHeme Oxygenase-1Herbal MedicineHumansNF-E2-Related Factor 2Oxidative StressHeme Oxygenase-1NF-E2-Related Factor 2Pharmaceutical Preparations7-HMR, (−)-7(S)-hydroxymatairesinolADH, andrographolideAGE, advanced glycation end productAkt, protein kinase BAMP, Athyrium MultidentatumAng, AngiotensinApoE, apolipoprotein EAPV, aqueous extracts of Prunella VulgarisARE, antioxidant reaction elementsAS, atherosclerosisASD-IV, Astragaloside IVASP, Angelica sinensis polysaccharideASTP, Astragalus polysacharinAtherosclerosisBAECs, bovine artery endothelial cellsBBR, BerberineBITC, benzyl isothiocyanateC3G, Cyanidin-3-O-glucosideCINM, CinnamaldehydeCNC, Cap'n'collarCREB, cAMP-response element binding proteinCVDs, cardiovascular diseasesCVRF, cardiovascular risk factorsDMY, DihydromyricetinECC, (−)-EpicatechinECs, endothelial cellsEGCG, epigallocatechin-3-O-gallateeNOS, endothelial NO synthaseERK, extracellular regulated protein kinasesET, endothelinEXS, Xanthoceras sorbifoliaFFA, Fatty AcidsGau A, Glaucocalyxin AGPx, Glutathione peroxidaseGSD Rg1, Ginsenoside Rg1GTE, Ganoderma tsugae extractsHAMS, human anthocyanin medicated serumHcy, HomocysteineHerbal medicineHG, high glucoseHIF-1, Hypoxia-inducible factor 1HO-1, heme oxygenaseHUVECs, human umbilical vein endothelial cellsHXC, Huoxue capsuleICAM, intercellular adhesion moleculeIL, interleukinKeap1, kelch-like epichlorohydrin-related proteinsKGRE, extracts of KGRKRG, Korean red ginsengLWDH, Liuwei-Dihuang pillMA, maslinic acidMAPKK, mitogen-activated protein kinase kinaseMAPKs, mitogen-activated protein kinasesMCGA3, 3-O-caffeoyl-1-methylquinic acidMCP-1, monocyte chemotactic protein 1MMPs, matrix metalloproteinasesMolecular mechanismNAF, Nepeta AngustifoliaNF-κB, nuclear factor kappa-BNG, naringeninNQO1, NAD(P)H: quinone oxidoreductaseNrf2/HO-1 signalingNrf2, nuclear factor erythroid-2 related factor 2OA, Oleanolic acidOMT, OxymatrineOxidative stressOX-LDL, oxidized low density lipoproteinPAA, Pachymic acidPAI-1, plasminogen activator Inhibitor-1PA, PalmitatePEITC, phenethyl isocyanatePI3K, phosphatidylinositol 3 kinasePKC, protein kinase CPT, PterostilbeneRBPC, phenolic extracts derived from rice branROS, reactive oxygen speciesSal B, salvianolic acid BSAL, SalidrosideSchB, Schisandrin BSFN, sulforaphaneSMT, Samul-Tang TangSOD, superoxide dismutaseTCM, traditional Chinese medicineTNF, tumor necrosis factorTrxR1, thioredoxin reductase-1TXA2, Thromboxane A2US, uraemic serumVascular endothelial cellsVA, Vanillic acidVCAM, vascular cell adhesion moleculeVEC, vascular endothelial cellsVEI, vascular endothelial injuryXAG, xanthoangelolXXT, Xueshuan Xinmaining TabletZ-Lig, Z-ligustilide

Identifiers

PMID35024180
PMCPMC8655139
OpenAlexW3178476896

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.